CTMX CytomX Therapeutics, Inc.
Healthcare$3.76+0.00%ClosedMarket Cap: $604.7M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
2.08
P/S
17.01
EV/EBITDA
-9.36
DCF Value
$-4.75
FCF Yield
-13.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.3%
Operating Margin
-181.9%
Net Margin
-166.4%
ROE
-36.6%
ROA
-16.5%
ROIC
-19.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $10.3M | 97.6% | $-19.7M | $-18.2M | $— | — |
| Q4 null | $663.0K | 100.0% | $-27.9M | $-26.5M | $— | — |
| FY null | $76.2M | 100.0% | $-22.4M | $-17.4M | $— | — |
| Q3 null | $6.0M | 100.0% | $-15.8M | $-14.2M | $— | — |
| Q2 null | $18.7M | 100.0% | $-1.3M | $-154.0K | $— | — |
| Q1 null | $50.9M | 100.0% | $22.6M | $23.5M | $— | — |
| Q4 null | $38.1M | 100.0% | $17.7M | $18.9M | $— | — |
| FY null | $138.1M | 100.0% | $25.0M | $31.9M | $— | — |
| Q3 null | $33.4M | 100.0% | $4.1M | $5.7M | $— | — |
| Q2 null | $25.1M | 100.0% | $-8.5M | $-6.5M | $— | — |
| Q1 null | $41.5M | 100.0% | $11.7M | $13.8M | $— | — |
| Q4 2023 | $26.6M | 100.0% | $-606.0K | $837.0K | $0.01 | — |